Generation Bio Co (GBIO)

Etorro trading 970x250
Generation Bio Co (GBIO) Logo

About Generation Bio Co

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Generation Bio Co News and around…

Latest news about Generation Bio Co (GBIO) common stock and company :

Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
15 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company’s retina therapeutic area. “We are excited to share our preclinical data demonstrating broad

Director Of Generation Bio Makes $2.0M Sale
30 Sep, 2021 Yahoo! Finance

Jason Rhodes, Director at Generation Bio (NASDAQ:GBIO), made a large insider sell on September 29, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Rhodes sold 81,088 shares of Generation Bio at prices ranging from $24.59 to $25.70. The total transaction amounted to $2,059,519. Rhodes still owns a total of 1,167,545 shares of Generation Bio worth, $28,838,361. Generation Bio shares are trading up 1.69% at $24.

Analysts See 53% Upside For The Holdings of NIFE
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Fallen Knives ETF ETF (NIFE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.22 per unit.

48 Biggest Movers From Friday
20 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded ...

12 Health Care Stocks Moving In Friday's Intraday Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares rose 78.31% to $4.03 during Friday's regular session. The current volume of ...

Generation Bio Co. (NASDAQ:GBIO) insiders' US$600k purchase saw a boost of US$66k after market cap rose US$93m
17 Sep, 2021 Yahoo! Finance

Generation Bio Co. ( NASDAQ:GBIO ) insiders who bought shares over the past year were rewarded handsomely last week...

60 Biggest Movers From Yesterday
25 Aug, 2021 FinancialContent

Gainers Triple-S Management Corporation (NYSE: GTS) shares surged 45.5% to close at $35.20 on Tuesday. GuideWell Mutual Holding ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
24 Aug, 2021 FinancialContent

Gainers Triple-S Management (NYSE:GTS) shares moved upwards by 45.3% to $35.15 during Tuesday's regular session. As ...

38 Stocks Moving In Tuesday's Mid-Day Session
24 Aug, 2021 FinancialContent

Gainers Triple-S Management Corporation (NYSE: GTS) shares jumped 45.3% to $35.15. GuideWell Mutual Holding Corporation, parent ...

Analysts See 15% Gains Ahead For ESML
13 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.99 per unit.

12 Health Care Stocks Moving In Thursday's Intraday Session
12 Aug, 2021 FinancialContent

Gainers NanoVibronix (NASDAQ:NAOV) stock increased by 23.8% to $2.86 during Thursday's regular session. As of 12:30 ...

Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
11 Aug, 2021 FinancialContent
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
03 Aug, 2021 FinancialContent
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
14 Jul, 2021 FinancialContent
Generation Bio to Present at William Blair Biotech Focus Conference
08 Jul, 2021 FinancialContent
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
19 Jun, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysts Expect 29% Upside For WDNA
10 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $34.05 per unit.

Generation Bio to Present at the JMP Securities Life Sciences Conference
09 Jun, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2021
08 Jun, 2021 FinancialContent

Upgrades According to Seaport Global, the prior rating for CMC Materials Inc (NASDAQ:CCMP) was changed from Neutral to ...

Tuesday Sector Laggards: Diagnostics, Biotechnology Stocks
01 Jun, 2021 FinancialContent

In trading on Tuesday, diagnostics shares were relative laggards, down on the day by about 0.9%. Helping drag down the group were shares of Genetic Technologies, off about 10% and shares of Viemed Healthcare off about 6.3% on the day.

Generation Bio to Present at the Jefferies Virtual Healthcare Conference
27 May, 2021 FinancialContent
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
17 May, 2021 FinancialContent
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results
12 May, 2021 FinancialContent
Generation Bio Shows Market Leadership With Jump To 83 RS Rating
29 Apr, 2021 FinancialContent

Generation Bio sees its Relative Strength Rating hit the 80-plus level.

Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
27 Apr, 2021 FinancialContent
Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference
08 Apr, 2021 FinancialContent
GBIO Makes Bullish Cross Above Critical Moving Average
01 Apr, 2021 FinancialContent

In trading on Thursday, shares of Generation Bio Co (GBIO) crossed above their 200 day moving average of $28.89, changing hands as high as $29.31 per share. Generation Bio Co shares are currently trading up about 0.3% on the day..

Could The Generation Bio Co. (NASDAQ:GBIO) Ownership Structure Tell Us Something Useful?
21 Mar, 2021 Yahoo! Finance

A look at the shareholders of Generation Bio Co. ( NASDAQ:GBIO ) can tell us which group is most powerful. Large...

Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results
18 Mar, 2021 FinancialContent
Oxurion NV Business and Financial Update – FY 2020
17 Mar, 2021 FinancialContent

Generation Bio Co (GBIO) is a NASDAQ Common Stock listed in , ,

970x250